drugset / Trial / NCT02703350

A Study of LY900014 in Participants With Type 1 Diabetes on Insulin Injection Therapy

NCT02703350

Phase 1 Completed 30 enrolled Eli Lilly and Company
RandomizedCrossoverDouble-blindBasic science

Summary

The study will be conducted in participants with type1 diabetes on insulin injection therapy to investigate how the body processes LY900014 and the effect of LY900014 on blood sugar levels. Side effects and tolerability will be documented. The study will be conducted in two parts (Part A and Part B) to achieve its objectives. Participants are expected to enroll in both parts.

Timeline

Start
2016-03
Primary completion
2016-07
Completion
2016-07

Drugs

EvaluationDrugModalityDoseRoute
Comparator Insulin Lispro Protein / enzyme biologic Subcutaneous